Identifying Dry Eye Disease

Common Causes of Dry Eye Disease

Consequences of Untreated Dry Eye Disease

Evaluating Patients for Dry Eye Disease

Educating Patients About Dry Eye Disease

Layering Therapy for Dry Eye Disease

Omega-3 Fatty Acid Supplements for Dry Eye Disease

Artificial Tears for Dry Eye Disease

Corticosteroids for Dry Eye Disease

In-Office Procedures Used to Treat Dry Eye Disease

Optimizing Adherence to Therapies for Dry Eye Disease

Eye Care Products in the Pipeline for Dry Eye Disease

Closing Remarks: Personalizing Dry Eye Care

Videos

A panel of ophthalmologists and optometrists discuss the significance of addressing dry eye disease using various types of treatment strategies, including pharmacologic and non-pharmacologic options.

Exploring the Management of Dry Eye

Updates in diabetic macular edema, diabetic retinopathy

Diabetic Retinopathy imaging

Using OCT-A for patients with diabetes

Optimize diabetes health management

Diabetes management: OD and MD communication

Diabetes management challenges

ADA guidelines for managing DR/DME 

DR/DME treatment options

COVID-19 impact on management of DR/DME

Emerging treatment options for DR/DME

A panel of experts in ophthalmology and optometry review the diagnosis and treatment of diabetic eye disease including emerging agents in the field.

Updates: Diabetic macular edema and diabetic retinopathy

Introduction and overview

Consequences and epidemiology of untreated dry eye

Diagnosis and overlooking asymptomatic patients with DED

Standard testing and assessment for DED

General Principles of Treatment of DED

OD and MD communication for optimal care

Review of artificial tears for DED

Corticosteroids and Immunomodulators for the treatment of dry eye

The role of nutritional supplements and antibiotics in DED

How to treat meibomian gland dysfunction

In-office procedures and patient resistance for DED treatments

Treatments for aqueous dry eye

Challenges in the management of DED

Counseling and formulary concerns for DED therapies

Overlapping diseases and COVID-19's impact

Agents in the pipeline for DED

Novel agents in the pipeline for DED

Marguerite McDonald, MD, Eric Donnenfeld, MD, Tracy Swartz, OD, MS, FAAO, and Crystal Brimer, OD, FAAO, discuss a number of topics pertaining to dry eye, including the diagnosis and clinical manifestations, traditional, treatment options, and the potential new agents in the horizon.

Advancements in dry eye managment

Generic vs. Branded Ophthalmic Medications

Cost and Substitution Issues

Patient Counseling on Generic vs. Branded

Dry Eye Disease Epidemiology 

Impact of Dry Eye on Surgical Outcome; Patient Screening 

Glaucoma Medications and Dry Eye Disease 

Initiating Anti-Inflammatory/Immunomodulatory Therapy

Cyclosporine Formulation Challenges

Lifitegrast Experience and Patient Counseling 

Role of the Technician 

The Technician’s Role 

The ViewPoints Series is an interactive learning module featuring leading industry experts from across the eyecare spectrum. The series leverages the various perspectives of panel participants to create a meaningful conversation on a range of eye health topics and issues related to current clinical data and industry trends.

Viewpoints